Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Invitrocue (IVQ) has completed CE Mark registration for its Onco-PDO cancer test, enabling the sale of the product in the European Economic Region
  • The CE Mark requires a declaration that the product meets EU standards for health, safety and environmental protection
  • Onco-PDO will soon be commercially available to oncologists and patients across Europe, starting with Germany and Spain
  • Despite the good news, company shares are still locked up
  • Invitrocue stock has been suspended since August 2019, last trading for six cents each

Invitrocue (IVQ) has completed CE Mark registration for its Onco-PDO cancer test, enabling the sale of the product in the European Economic Region.

Headquartered in Singapore, with operations in Australia, China, Hong Kong and Germany, the company specialises in developing cell-based testing methods to provide key insights into liver toxicology, infectious diseases and oncology. 

Invitrocue’s Onco-PDO product offers an alternative to the “one-size-fits-all” approach that is common in treatments for cancer patients. 

The company’s proprietary test takes a more personalised approach, enabling medical professionals to prescribe the most appropriate treatment program based on cancer cell phenotypic resistance or the patient’s response to specific chemotherapeutic drugs.

Registration for the CE Mark requires a declaration from the company that the product meets all EU standards for health, safety and environmental protection. 

Dr. Andreas Lindner, CEO of Invitrocue Germany, commented on the milestone achievement.

“We are very pleased that Onco-PDO has successfully registered for the CE Mark, as Europe is a big market where we can offer our test,” Andreas explained.

“We are looking forward to helping doctors in the region make more informed decisions about the best treatment path for cancer patients,” he said.

Onco-PDO will soon be commercially available to oncologists and patients across Europe, starting in Germany and then Spain. Invitrocue also has plans to enter other markets, including Brazil.

The company will also be seeking to list the Onco-PDO test under the German Healthcare reimbursement system, although this is likely to occur later this year.

Despite the good news, company shares are still locked up.

Invitrocue stock has been suspended since August 2019, last trading for six cents each

IVQ by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.